Nath Bio-Genes (India) Ltd
Nath Bio-Genes (India) Q1 FY27 investor presentation: Revenue & Margins
Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on Nath Bio-Genes (India) Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q1FY27 Revenue: INR 3,228 Mn, up 15% YoY from INR 2,802 Mn in Q1FY26 (Page 23, 24, 25) - Gross Profit for Q1FY27: INR 1,629 Mn, up 13% YoY (Page 23, 25) - EBITDA for Q1FY27: INR 351 Mn, up 17% YoY Q1FY27 EBITDA: ₹351 Mn, up 17% YoY from ₹299 Mn in Q1FY26 - Q1FY27 Operating Margin (EBITDA Margin): 11%, steady YoY (11% in Q1FY26) - Q1FY27 PAT (excluding extraordinary items): ₹327 Mn
From Nath Bio-Genes (India) Ltd's Q1 FY27 earnings-call transcript · updated 9 Oct 2026.
Revenue & Sales Performance
- Q1FY27 Revenue: INR 3,228 Mn, up 15% YoY from INR 2,802 Mn in Q1FY26 (Page 23, 24, 25)
- Gross Profit for Q1FY27: INR 1,629 Mn, up 13% YoY (Page 23, 25)
- EBITDA for Q1FY27: INR 351 Mn, up 17% YoY (Page 23, 25)
- PBT after exceptional adjustments for Q1FY27: INR 334 Mn, up 12% YoY (Page 23, 25)
- Volume growth highlights (QoQ basis, Page 22):
- Maize: 44% volume growth, 59% value growth
- Paddy: 19% volume growth, 34% value growth
- Cotton, Bajra, Jowar: stable volume and value
2 more points from Nath Bio-Genes (India) Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Nath Bio-Genes (India) Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Agricultural Food & other Products
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Nath Bio-Genes (India) Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Nath Bio-Genes (India) Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Nath Bio-Genes (India) Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹52 Cr, net loss ₹0 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Nath Bio-Genes's management said in earlier quarters
Others in Agricultural Food & other Products this season
- Sanstar (Q1 FY27)
2,062 million, up 21.5% YoY from Rs. Key investor presentation takeaways from Sanstar Ltd's Q1 FY27 investor presentation — and how it ranks against sector peer
- Uttam Sug.Mills (Q1 FY27)
588.46 Cr vs Rs. Key investor presentation takeaways from Uttam Sugar Mills Ltd's Q1 FY27 investor presentation — and how it ranks against sector peers.
- NFP Sampoorna (Q1 FY27)
FY26 revenue grew 43% to INR 51 crore from INR 35 crore in FY25, driven by better capacity utilization and portfolio diversification. Key concall takeaways…
- Modi Naturals (Q1 FY27)
Q1FY27 consolidated revenue from operations: Rs 155.6 Cr, up 0.4% YoY from Rs 155.0 Cr in Q1FY26 (Page 10, 6). Key investor presentation takeaways from Modi Nat
Arthneeti Pro · Annual
Nath Bio-Genes (India) Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Nath Bio-Genes (India) Ltd Q1 FY27 results?
Q1FY27 Revenue: INR 3,228 Mn, up 15% YoY from INR 2,802 Mn in Q1FY26 (Page 23, 24, 25) - Gross Profit for Q1FY27: INR 1,629 Mn, up 13% YoY (Page 23, 25) - EBITDA for Q1FY27: INR 351 Mn, up 17% YoY Q1FY27 EBITDA: ₹351 Mn, up 17% YoY from ₹299 Mn in Q1FY26 - Q1FY27 Operating Margin (EBITDA Margin): 11%, steady YoY (11% in Q1FY26) - Q1FY27 PAT (excluding extraordinary items): ₹327 Mn
What is Nath Bio-Genes (India) Ltd share price analysis?
Nath Bio-Genes (India) Ltd currently shows a neutral. The stock trades at a P/E of 8.4 with a market cap of ₹284 Cr. Investors should review the full earnings analysis for detailed insights.
Is Nath Bio-Genes (India) Ltd planning capital expenditure?
The investor presentation does not explicitly describe any capex, capacity expansion, or new plant/project details including amounts, status, or timelines.
Keep Nath Bio-Genes (India) Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.